What began as an interdisciplinary research initiative supported by philanthropic seed funding at MIT has given rise to General Biology, an AI × Bio company with an ambitious mission: to make chronic diseases preventable through advances in artificial intelligence and multi-omic biology. An MIT/Broad Institute spinout, General Biology is launching with support from the Alzheimer's Disease Data Initiative to develop a new generation of biological foundation models that transform how chronic diseases are understood, prevented, and treated, initially focusing on Alzheimer's disease.
The company emerged from FINGERPRINT, an international research initiative founded by Adrián Noriega, Arvid Gollwitzer, Picower Professor Li-Huei Tsai, Miia Kivipelto, and Karl Van Tassel (1925) Professor Giovanni Traverso, bringing together scientists, physicians, and AI researchers from the MIT, the Broad Institute of MIT and Harvard, Karolinska Institutet, and the FINGERS Brain Health Institute.
Above: The founding team of FINGERPRINT and General Biology: Giovanni Traverso, Miia Kivipelto, Arvid Gollwitzer, Li-Huei Tsai, and Adrián Noriega.
FINGERPRINT originated with a philanthropic seed grant from MIT's Aging Brain Initiative (ABI) to Adrián Noriega, MIT-Novo Nordisk AI Fellow, and Traverso, a professor of mechanical engineering. Tsai, a professor in The Picower Institute for Learning and Memory and Department of Brain and Cognitive Sciences, directs the ABI.
Within months of receiving this initial support, the team developed FINGERS-7B, the first AI foundation model designed specifically for Alzheimer's prevention, identified novel multiomic biomarkers for preclinical Alzheimer's disease, and demonstrated the model's potential to predict individual responses to preventive interventions.
"When we established the Aging Brain Initiative, our vision was to bring together scientists across disciplines to tackle some of the most fundamental challenges in brain health and aging," Tsai said. "FINGERPRINT and now General Biology, exemplifies what becomes possible when neuroscience, artificial intelligence, and clinical research come together. It is particularly exciting to see how philanthropic support for early-stage research can catalyze scientific breakthroughs and open new avenues for technological and therapeutic innovation."
Learning from Human Biology to Prevent Disease
FINGERS-7B is a 7-billion-parameter foundation model that integrates genomic, proteomic, clinical, and lifestyle data from tens of thousands of individuals, drawing on Kivipelto's landmark FINGER study and the World-Wide FINGERS Network.
"Each of us carries a unique biological fingerprint that can reveal not only our disease susceptibility, but also how we might respond to different interventions," said Noriega, who co-leads FINGERPRINT with Gollwitzer. "Understanding these differences could fundamentally change how we approach the prevention and treatment of Alzheimer's and other chronic diseases."
Unlike conventional approaches that examine individual biological signals in isolation, FINGERS-7B learns across multiple molecular domains to characterize differences in disease risk, progression, and response to intervention.
"Learning jointly from molecular, clinical, and intervention data, foundation models offer a fundamentally new way to study human biology," said Gollwitzer, who led the design and training of FINGERS-7B. "We can begin to understand not only how diseases develop, but how interventions might change their trajectories."
A version of FINGERS-7B will be made available to the global research community through the AD Workbench, supporting further scientific discovery and international collaboration in Alzheimer's prevention.
Academic discovery to engineering precision prevention
The launch of General Biology represents the next stage in translating FINGERPRINT's scientific advances, Noriega and Gollwtizer said. The company's founding team brings together complementary expertise in artificial intelligence, neuroscience, global clinical prevention trials, therapeutic development, and biotechnology entrepreneurship.
General Biology is an MIT/Broad Institute spin-off, with the Alzheimer's Disease Data Initiative among its earliest supporters, and will focus on developing multi-omic foundation models to uncover disease mechanisms, discover preventive therapies, identify promising therapeutic combinations, and predict individual treatment responses.
"One of the most promising opportunities in Alzheimer's research is to move beyond understanding who is at risk to identifying which interventions can meaningfully alter the trajectory of disease," said Niranjan Bose, Interim Executive Director, AD Data Initiative. "The convergence of artificial intelligence, multi-omic biology, and longitudinal clinical research offers a new path toward making precision prevention a reality."
Starting with Alzheimer's disease, General Biology aims to extend its approach to other chronic diseases, connecting advances in artificial intelligence and human biology with evidence from clinical intervention studies to transform how diseases are understood, prevented, and treated.
Learn more about FINGERPRINT and General Biology.

